Analytic aspects of monitoring therapy with thiopurine medications

被引:35
作者
Armstrong, VW
Shipkova, M
von Ahsen, N
Oellerich, M
机构
[1] Univ Gottingen, Zentrum Innere Med, Klin Chem Abt, D-37075 Gottingen, Germany
[2] Klinikum Stuttgart, Inst Clin Chem & Lab Med, D-70174 Stuttgart, Germany
关键词
azathioprine; mercaptopurine; thioguanine; thiopurine methyltransferase; thioguanine nucleotides;
D O I
10.1097/00007691-200404000-00024
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The thiopurine medications 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathioprine are used in treatment of childhood acute lymphoblastic leukemia, amoimmune diseases, and, in the case of azathioprine, in solid organ transplantation. They are converted in vivo to the active 6-thioguanine nucleotides (6-TGN). One person in 300 in white populations has low or undetectable TPMT activity and is at risk for accumulating 6-TGN with the consequence of severe, life-threatening myelosuppression. A rational therapeutic strategy for thiopurine drug use is to first determine TPMT phenotype/genotype and then to adjust the dosage on an individual basis. Determination of erythrocyte 6-TGN levels can further help to optimize therapy. TPMT activity (phenotype) is determined in erythrocytes using radiochemical or HPLC procedures. Recent HPLC procedures show good agreement with the original radiochemical method, while offering simplified sample pretreatment and improved precision. To date, 12 mutant alleles responsible for TPMT deficiency have been published. Restriction fragment length polymorphism PCR and allele-specific PCR have been used for detection of TPMT mutations. Genotyping methods that allow a higher throughput include real-time PCR (LightCycler) and denaturing HPLC. Numerous HPLC methods have been reported for quantification of 6-TGN. The majority involve acid hydrolysis to 6-TG at high temperature. There are substantial differences in the hydrolysis step, extraction procedure, chromatographic conditions and method of detection. Erythrocyte 6-TGN concentrations can vary up to 2.6-fold depending on the HPLC method. The method that has found the greatest application in clinical studies is that of Lennard.(46) This has served as the basis for the establishment of treatment-related therapeutic ranges for thiopurine therapy. These ranges will not necessarily be applicable when other methodology is used. There is an urgent need to harmonize the analytic procedures for 6-TGN.
引用
收藏
页码:220 / 226
页数:7
相关论文
共 53 条
  • [1] Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation
    Anglicheau, D
    Sanquer, S
    Loriot, MA
    Beaune, P
    Thervet, E
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 773 (02): : 119 - 127
  • [2] Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
    Bergan, S
    Rugstad, IE
    Bentdal, O
    Sodal, G
    Hartmann, A
    Leivestad, T
    Stokke, O
    [J]. TRANSPLANTATION, 1998, 66 (03) : 334 - 339
  • [3] Possibilities for therapeutic drug monitoring of azathioprine: 6-Thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
    Bergan, S
    Rugstad, HE
    Klemetsdal, B
    Giverhaug, T
    Bentdal, O
    Sodal, G
    Hartmann, A
    Aarbakke, J
    Stokke, O
    [J]. THERAPEUTIC DRUG MONITORING, 1997, 19 (03) : 318 - 326
  • [4] Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: Relevance to toxicity and monitoring in recipients of renal allografts
    Bergan, S
    Bentdal, O
    Sodal, G
    Brun, A
    Rugstad, HE
    Stokke, O
    [J]. THERAPEUTIC DRUG MONITORING, 1997, 19 (05) : 502 - 509
  • [5] Boulieu R, 2001, CLIN CHEM, V47, P956
  • [6] Pitfalls in the determination of mutant alleles of the thiopurine methyltransferase gene
    Brouwer, C
    Marinaki, A
    Lambooy, L
    Duley, J
    Shobowale-Bakre, M
    De Abreu, RA
    [J]. LEUKEMIA, 2001, 15 (11) : 1792 - 1793
  • [7] The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs
    Coulthard, SA
    Hogarth, LA
    Little, M
    Matheson, EC
    Redfern, CPF
    Minto, L
    Hall, AG
    [J]. MOLECULAR PHARMACOLOGY, 2002, 62 (01) : 102 - 109
  • [8] 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
    Cuffari, C
    Theoret, Y
    Latour, S
    Seidman, G
    [J]. GUT, 1996, 39 (03) : 401 - 406
  • [9] Dervieux T, 1998, CLIN CHEM, V44, P551
  • [10] Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
    Dubinsky, MC
    Lamothe, S
    Yang, HY
    Targan, SR
    Sinnett, D
    Théorêt, Y
    Seidman, EG
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : 705 - 713